Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 7Active not recruiting 6Recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 9Recurrence 7Lymphoma, Non-Hodgkin 7Neoplasms 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Blood Protein Disorders 1

Interventions

Dexamethasone 4iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Curcumin 2Calcium Dobesilate 2selinexor 1isatuximab 1daratumumab 1Resistance Training 1Propranolol 1Probiotics 1Docosahexaenoic Acids 1Dietary Fiber 1Diet, Plant-Based 1Diet, Mediterranean 1Blood Specimen Collection 1Behavior Therapy 1Adrenergic beta-Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Smoldering Multiple Myeloma × Lenalidomide × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT05469893 2025-04-24

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Dana-Farber Cancer Institute

Phase 2 Recruiting
52 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡